United States – October 27, 2026 -- Truveta aims to enroll tens of millions of consenting participants in the Truveta Genome Project. The goal is the largest and most diverse database of genotypic and phenotypic information ever assembled, according to Kristin Rand, the company's Senior Director of Genomics Partnerships.
The project has moved from planning to enrolling participants and collecting samples, roughly 15 months after Truveta announced it. It builds a consented, de-identified genomic dataset linked with longitudinal clinical data, treatments and outcomes. Truveta has not disclosed current enrollment figures or the number of participating health systems.
Truveta sponsors a centralized multi-site research protocol
Truveta is the study sponsor. Each participating health system assigns its own site principal investigator upon enrollment. Truveta says this structure reduces administrative burden and accelerates deployment while letting health systems keep local oversight and meet local requirements.
Health systems lead enrollment and informed consent
Participating health systems run participant enrollment and the informed consent process. Truveta says it developed a patient-centered protocol and consent process for the genetic samples being collected, and that it worked with each health system on the structure needed for large-scale research.
Linked clinical data targets differences in treatment response
Truveta says a genetic variant's value emerges only when it is linked to phenotypes, treatments and outcomes across large, diverse populations over time. The questions it names include why two patients on the same therapy experience vastly different outcomes and how to detect disease risk earlier, before irreversible harm occurs.
As more health systems join, Truveta plans to refine its approach to scale. Greater scale would also let researchers study genomic information alongside other types of biological and clinical data.